TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Saniona AB ( (SE:SANION) ) just unveiled an announcement.
Saniona AB has announced a Q3 investor call scheduled for 27 November 2025, where management will present results and provide a company update. This call is an opportunity for stakeholders to gain insights into Saniona’s operational progress and strategic direction, potentially impacting its industry positioning and stakeholder interests.
The most recent analyst rating on (SE:SANION) stock is a Buy with a SEK18.50 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.
More about Saniona AB
Saniona is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for neurological and psychiatric disorders. The company has a robust internal pipeline targeting conditions such as epilepsy and major depressive disorder, and has established strategic collaborations with major pharmaceutical companies like Jazz Pharmaceuticals and Acadia Pharmaceuticals. Saniona is headquartered in Copenhagen and listed on the Nasdaq Stockholm Main Market.
Average Trading Volume: 1,340,926
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.24B
Find detailed analytics on SANION stock on TipRanks’ Stock Analysis page.